Guardant Health's Shield Blood Test Outperforms Stool-Based CRC Screening in Adherence and Mortality Reduction
Event summary
- Guardant Health presented data at the ACG 2026 Annual Meeting showing its Shield blood test significantly increases CRC screening adherence and averts more deaths compared to stool-based tests.
- A modeling study projected Shield increased colonoscopies (679 vs. 113 and 326) and averted more CRC deaths (12 vs. 6 and 9) per 1,000 simulated individuals over a lifetime.
- Real-world adherence in South Carolina clinics reached 99%, far exceeding average CRC screening adherence rates of 28-71%.
- Shield has been used in over 200,000 real-world tests, demonstrating over 90% screening adherence.
The big picture
Guardant Health's Shield blood test is positioning itself as a disruptive force in colorectal cancer screening, addressing critical adherence gaps in underserved communities. The data presented at ACG 2026 underscores the strategic shift from stool-based tests to blood-based screening, which could redefine CRC screening pathways and improve health outcomes. With over 200,000 tests performed, Shield is gaining traction as a clinically validated alternative, potentially reshaping the competitive landscape in cancer screening.
What we're watching
- Adoption Dynamics
- How Guardant Health will scale Shield's adoption in medically-underserved communities where screening gaps are most persistent.
- Competitive Positioning
- Whether Shield can maintain its clinical advantage over emerging blood-based CRC screening alternatives.
- Regulatory Landscape
- The pace at which regulatory approvals expand for blood-based screening tests beyond average-risk populations.
Related topics
